April 1 (Reuters) - Elanco Animal Health ( ELAN ) said

on Monday that it had appointed two new directors to its board

after reaching an agreement with activist investor Ancora

Holdings but stopped short of naming a new CEO.

The company that makes medicines and vaccinations for

pets and livestock said it has added Kathy Turner and Craig

Wallace to the board of directors.

The investment firm, which holds about a 2% stake in the

company, had said in

February

that it wanted four board seats at Elanco and to replace

CEO Jeffrey Simmons over "poor performance."

Craig Wallace is a former senior executive at French

animal health company Ceva Santé Animale, and Kathy Turner has

previously been a senior executive at animal healthcare company

IDEXX Laboratories ( IDXX ).